Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26198
Title: | There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF). | Austin Authors: | Nambiar, Shabarinath;Clynick, Britt;How, Bong S;King, Adam;Walters, E Haydn;Goh, Nicole S L ;Corte, Tamera J;Trengove, Robert;Tan, Dino;Moodley, Yuben | Affiliation: | Fiona Stanley Hospital, Murdoch, WA, Australia Austin Health Institute for Breathing and Sleep University of Sydney, Camperdown, NSW, Australia Royal Prince Alfred Hospital, Camperdown, NSW, Australia School of Biomedical Science, University of Western Australia, Crawley, WA, Australia Institute for Respiratory Health, Nedlands, WA, Australia Separation Science and Metabolomics Laboratory, Murdoch University, Murdoch, WA, Australia Metabolomics Australia, Murdoch University, Murdoch, WA, Australia Alfred Hospital, Melbourne, VIC, Australia University of Tasmania, Hobart, TAS, Australia University of Melbourne, Parkville, VIC, Australia Royal Hobart Hospital, Hobart, TAS, Australia Scientific Operations, Waters Corporation, Stamford Avenue, Wilmslow, SK9 4AX, UK |
Issue Date: | 9-Apr-2021 | Date: | 2021-04-09 | Publication information: | Respiratory Research 2021; 22(1): 105 | Abstract: | Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by fibrosis and progressive loss of lung function. The pathophysiological pathways involved in IPF are not well understood. Abnormal lipid metabolism has been described in various other chronic lung diseases including asthma and chronic obstructive pulmonary disease (COPD). However, its potential role in IPF pathogenesis remains unclear. In this study, we used ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) to characterize lipid changes in plasma derived from IPF patients with stable and progressive disease. We further applied a data-independent acquisition (DIA) technique called SONAR, to improve the specificity of lipid identification. Statistical modelling showed variable discrimination between the stable and progressive subjects, revealing differences in the detection of triglycerides (TG) and phosphatidylcholines (PC) between progressors and stable IPF groups, which was further confirmed by mass spectrometry imaging (MSI) in IPF tissue. This is the first study to characterise lipid metabolism between stable and progressive IPF, with results suggesting disparities in the circulating lipidome with disease progression. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26198 | DOI: | 10.1186/s12931-021-01682-3 | ORCID: | 0000-0002-8777-6877 | Journal: | Respiratory Research | PubMed URL: | 33836757 | Type: | Journal Article | Subjects: | DIA IPF Lipids MS Plasma SONAR |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.